Peptide library

5-Amino-1MQ is a small synthetic molecule, not a peptide, that blocks the enzyme NNMT. It is sold beside peptides, mostly as 50 mg oral capsules and sometimes as injectable vials. In obese mice it cut body weight and fat without changing food intake. No human trial exists, so every human dose you see is community or guide practice, and oral and injected doses sit on very different scales.

Adamax is a nootropic peptide sold as a longer-lasting Semax. Its developer describes it as Semax with an acetyl cap on the front and an adamantane group on the back, and has said it launched with no research of any kind. We found no human study, no animal study and no pharmacokinetic data. Two versions circulate, about 984 Da without adamantane and about 1032 Da with it, and some buyers report lab tests showing plain N-acetyl Semax. Every dose on this page is a vendor suggestion or a user report.

Adipotide (FTPP, prohibitin-TP01) is a designed peptide that homes to the blood vessels feeding white fat and switches on cell death there, so the fat loses its blood supply. Obese monkeys lost 7 to 15% of body weight in 4 weeks. The same study found dose-dependent kidney changes that mostly reversed after stopping. A first human trial was terminated after 4 patients with no results posted, so every human dose in use today comes from community practice.

A copper tripeptide, alanine, histidine, lysine, sold for thinning hair. It is GHK-Cu with one amino acid swapped. The evidence is one 2007 lab study on human hair follicles and a mouse patent; no human trial exists. Most people use it as a scalp serum, and injected doses are borrowed from GHK-Cu.

AOD-9604 is a 16 amino acid fragment of the tail end of human growth hormone, built to keep GH's fat-burning signal without its growth effects. It was developed as an oral obesity drug, and its biggest trial failed to beat placebo. Today people inject it under the skin, usually next to a GLP-1, at doses no trial ever tested. It is not FDA approved, has no lawful 503A compounding route, and is banned in sport.

An 11-amino-acid peptide cut from the helix-B face of erythropoietin (EPO). It switches on EPO's repair and anti-inflammatory signal without making red blood cells. Unusually for a research peptide, it has small human Phase 2 trials for nerve pain in sarcoidosis and diabetes, mostly at 4 mg a day for 28 days. It never reached Phase 3.

A synthetic 15 amino acid peptide (GEPPPGKPADDAGLV, about 1,419 Da) based on a fragment of a protein in human gastric juice. People run it for tendons, muscles, joints and the gut. The animal data run deep. The human data are three tiny uncontrolled reports, with real trials only now registered. Not approved anywhere.

BPC-157 and TB-500 in one vial at 1:1: a 10 mg vial holds 5 mg of each, a 20 mg vial 10 mg of each. It is the best-known healing stack. The catch is the fixed ratio: BPC-157 is usually dosed daily and TB-500 in big weekly loads, so one vial cannot copy both schedules. No human trial has tested the pair at these doses.

Cagrilintide is a long-acting, lab-made version of amylin, the fullness hormone your pancreas releases with insulin after meals. Novo Nordisk added a fatty-acid chain so one shot lasts about a week. It hits a different receptor family from GLP-1 drugs, so most people use it as an add-on to semaglutide, tirzepatide or retatrutide. Paired with semaglutide it is CagriSema, which has phase 3 data and a pending FDA filing. Cagrilintide on its own is not approved anywhere.

CagriSema is Novo Nordisk's once-weekly pairing of cagrilintide, a long-acting amylin copy, with semaglutide, the GLP-1 drug in Wegovy. The two hit different fullness signals, so the effects add up: 20.4% average weight loss at 68 weeks in REDEFINE 1. Novo filed for FDA approval in December 2025. Until a decision lands, the only versions outside trials are research blends sold as premixed vials, which are not Novo's formulation.

Cartalax is a synthetic three-amino-acid peptide (Ala-Glu-Asp, or AED) from Vladimir Khavinson's bioregulator program, sold as a cartilage and joint peptide. Guides run 2 to 5 mg a day by subQ injection, often ramped over 12 weeks, or 20 mg a day by mouth for 10 days. Every dose traces to guides and community practice; the indexed research is cell cultures plus one rat bone study. No human trial has tested a dose. Not FDA approved.

A prescription drug made from enzyme-digested pig brain protein: a mix of short peptides and amino acids, 215.2 mg per mL, given by injection or IV infusion. Approved in Austria and widely used in Russia, Eastern Europe and Asia for stroke, brain injury and dementia. Not approved in the US. Nootropic users run short IM courses.

CJC-1295 is a lab-made GHRH analog that tells the pituitary to release more growth hormone. It comes in two very different forms. With DAC it binds to albumin and works for about a week. Without DAC (Mod GRF 1-29) it clears in hours and gives a short pulse. Labels often say 'CJC-1295' for the no-DAC product, so check which one you have before you dose.

The most popular GH peptide pairing. CJC-1295 without DAC (Mod GRF 1-29) amplifies the growth hormone pulse, and ipamorelin triggers it. It comes as two vials or one pre-mixed vial. The common 10 mg blend holds 5 mg of each, not 10 mg of each. No human trial has tested this pair, so every dose here is a guide or community convention.

An angiotensin IV analog (about 505 Da) made at Washington State University to be stable, oral and brain-penetrant. Rat work called it a powerful synapse builder through HGF and c-Met, but the two core mechanism papers were retracted in 2025 and a third carries an expression of concern. It has never been tested in a human trial. Users take 5 to 20 mg by mouth, under the tongue or on the skin in DMSO.

DSIP is a 9-amino-acid peptide found in 1977 in the blood of sleeping rabbits and named for deep, slow-wave sleep. People inject 100 to 300 mcg before bed hoping to fall asleep faster and sleep deeper. The catch: no receptor has ever been found, the human trials are small 1980s IV studies with mixed results, and plenty of users on r/Peptides report it did nothing or kept them awake. It is not FDA approved, and an FDA panel voted against allowing it in compounding in July 2026.

Eloralintide is Eli Lilly's once-weekly amylin drug, built to favor the amylin 1 receptor instead of hitting amylin and calcitonin receptors the way cagrilintide does. In a 48-week phase 2 trial it cut weight by 9% at 1 mg up to 20% at 9 mg. It lasts about two weeks in the body. It is in phase 3 and not approved anywhere, and Lilly is also pairing it with tirzepatide as EloraTZP.

Epitalon is a synthetic four amino acid peptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a Russian pineal gland extract. People take it for longevity and telomeres, but sleep is what they report most. Guides run 5 to 10 mg a day for 10 to 20 days, a figure that traces to the extract. The human epitalon studies used 0.01 to 0.5 mg. Not FDA approved.

Follistatin is a protein your body already makes. It grabs myostatin, the signal that caps how much muscle you can carry. FS344 is the 344-amino-acid precursor that becomes FS315 in the blood. The headline muscle gains come from gene therapy in mice, monkeys and two small human trials, not from injecting the protein. Gray-market 1 mg vials run 50 to 200 mcg a day for short cycles, and one lab found real follistatin in only 9 of 17 products.

A synthetic senolytic: a 46 amino acid D-retro-inverso peptide that makes senescent cells self-destruct by blocking FOXO4 from holding p53. In a 2017 mouse study it restored fur, fitness and kidney function in old mice. Nobody has tested it in people. Users run short pulses of a few doses every other day, then stop for months.

A three amino acid peptide (glycine, histidine, lysine) bound to copper. Your body makes it: plasma levels run about 200 ng/mL at 20 and 80 ng/mL by 60. People use it for skin, hair and healing, on the skin or by injection. The human evidence is all topical. Injection has none, and the injected dose varies 10 to 30 fold between guides.

GHRP-2 and GHRP-6 are two six-amino-acid peptides that switch on the ghrelin (hunger hormone) receptor. That fires a GH pulse and, to different degrees, raises appetite, cortisol and prolactin. GHRP-2 gives more GH per mcg with milder hunger. GHRP-6 brings strong hunger, which is why bulkers like it. GHRP-2 is a licensed diagnostic drug in Japan; neither is approved in the US.

One vial holding GHK-Cu, BPC-157 and TB-500 at 5:1:1, 70 mg in total. GHK-Cu is about 71% of every draw, so this is a copper-peptide product with repair peptides riding along. It is a seller formulation, not a tested drug, and the name GLOW is also used loosely for copper-peptide skincare.

Glutathione is the antioxidant tripeptide every cell makes from glutamate, cysteine and glycine. People inject it for skin glow and liver support, and clinics drip it for skin lightening. Home users run 100 to 200 mg subQ or IM two to three times a week, a dose no trial has tested; trials used 600 to 1,400 mg IV or IM, 250 to 1,000 mg a day by mouth. It clears blood in about 14 minutes. Not FDA approved; on FDA's 503A Category 1 list.

Gonadorelin is synthetic GnRH, the brain signal that makes the pituitary release LH and FSH. FDA approved it as Factrel, a 100 mcg diagnostic test, and as Lutrepulse, a fertility pump; both are now discontinued. TRT users take compounded gonadorelin, usually 100 to 200 mcg two or three times a week, to keep the testes working in place of hCG. That use has no trial behind it, and its half-life is minutes.

Hexarelin is a six-amino-acid peptide built from GHRP-6, and guides rank it the strongest GH releaser in the GHRP family; in head-to-head IV tests it matched GHRP-2. The catch: each dose also lifts prolactin and cortisol, and the GH response fades with daily use, then recovers after a few weeks off. People run it in short blocks, usually with a GHRH analog. It was never marketed.

A 16-amino-acid piece from the tail end of human growth hormone, sold as a research peptide for fat loss. It releases no growth hormone. No human trial has tested it; the data are rodent and cell studies, and most of those used the related AOD-9604. Even the sequence in the vial varies by seller.

A 24 amino acid peptide coded in mitochondrial DNA, a sibling of MOTS-c. It protects cells from stress-driven death and falls with age; children of centenarians carry more of it. Most animal work uses HNG, a single-swap analog reported about 1000 times more potent, and vials sold as humanin may be either. No human has been given it in a trial.

IGF-1 LR3 is a lab-made version of IGF-1, the hormone GH tells your liver to make. Two changes keep it from sticking to the binding proteins that normally park IGF-1, so more of it is free to act. It was built as a cell-culture reagent, not a drug, and has never been tested in a human study. Bodybuilders run it at 20 to 40 mcg a day, with carbs.

Ipamorelin is a five-amino-acid peptide that triggers a short burst of your own growth hormone. It is a GH secretagogue, not GH. People like it because, in the animal work that defined it, it released GH without the cortisol bump other GHRPs cause. Human data are short IV studies only, so the doses people run come from guides and community convention.

Kisspeptin is the hormone that sits at the top of the reproductive axis: it tells the brain to release GnRH, which drives LH, FSH and testosterone. Vendors sell kisspeptin-10, the short 10-amino-acid form, usually as a 10 mg vial. Guides run 100 to 200 mcg a day under the skin. Human studies are real but small, mostly IV infusions and kisspeptin-54. FDA put kisspeptin-10 on its Category 2 compounding list, and WADA bans it in men.

One 80 mg vial holding four peptides at 5:1:1:1: GHK-Cu 50 mg plus BPC-157, TB-500 and KPV at 10 mg each. GHK-Cu is 62.5% of every draw. KLOW is a seller formulation name, not a compound, and nobody has studied it. The biggest dosing risk is the water: five competitors call four different volumes standard.

The last three amino acids (lysine, proline, valine; about 342 Da) of alpha-MSH. It is studied as an anti-inflammatory, mainly for the gut. It does not tan you. No human trial has tested it at any dose by any route. The animal data are oral, yet most guides lead with injection.

Liraglutide is Novo Nordisk's once-daily GLP-1 receptor agonist, the older sibling of semaglutide. It is FDA approved as Victoza for type 2 diabetes and as Saxenda for weight, with generics of both since 2024 and 2025. The weight dose climbs from 0.6 mg to 3 mg a day over five weeks. In SCALE, 3 mg averaged 8.4 kg lost vs 2.8 kg on placebo at 56 weeks, and in the only head-to-head trial weekly semaglutide lost more than twice as much. It is still on the FDA shortage list, which keeps compounded vials around.

LL-37 is the only cathelicidin humans make: a 37 amino acid antimicrobial peptide released by white cells, skin and gut lining. People inject 100 to 250 mcg a day for infection, gut and immune goals, but no injection has been tested in people. The human trials are topical, on leg and foot ulcers, with mixed results.

Mazdutide is a once-weekly injected peptide that hits the GLP-1 and glucagon receptors. Lilly and Innovent develop it, and China approved it in 2025 as Xinermei, first for weight management and then for type 2 diabetes. In Chinese phase 3 trials it cut weight 11.0% at 4 mg and 14.0% at 6 mg over 48 weeks, and 16.65% at 9 mg over 60 weeks. Outside China it is investigational, and US research-vial sellers draw FDA warning letters.

Melanotan 1 is afamelanotide, a lab-made alpha-MSH that switches on the skin's pigment receptor. It is FDA approved as Scenesse, a 16 mg implant given every 2 months to adults with EPP, a painful sun-sensitivity disease. Unapproved MT1 vials are used to tan: about 0.25 to 1 mg daily to load, then twice a week. It tans slower than MT2 with milder side effects, and freckles and moles still darken.

Melanotan II (MT-2) is a synthetic, cyclic version of alpha-MSH that darkens skin, often with little sun. It also drives libido and cuts appetite because it hits several melanocortin receptors. People load it daily at about 100 to 500 mcg, then hold the colour with 1 or 2 shots a week. Nausea and flushing are the price early on, and moles darken too. It is approved nowhere.

MK-677 is the GH booster in a pill, and it is not a peptide at all: ibutamoren is a small molecule that switches on the same ghrelin receptor as GHRP-6 and ipamorelin. One 25 mg dose a day kept GH and IGF-1 at young-adult levels for 2 years in older adults. The trade-offs are hunger, water retention and higher blood sugar, plus a heart-failure signal in frail patients. Never approved.

A 16 amino acid peptide the body makes from a gene inside mitochondria. In mice it acts like an exercise signal for metabolism, and blood levels rise with exercise in people. Users run it for fat loss, energy and longevity, often next to a GLP-1 or SS-31. Nobody has measured a human dose or half-life. The first real trial started in 2026. It is banned in sport.

Selank with two chemical caps: an acetyl group on the front of the chain and an amide on the back (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2). Sellers and guides say the caps make it more stable and 2 to 3 times stronger than Selank. No study of any kind has tested it. People use it for anxiety and calm, by nasal spray or under the skin, often with N-acetyl Semax amidate. One seller calls it Adalank, a name others use for a different peptide.

Semax with two chemical caps: an acetyl group on the front of the chain and an amide on the back (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2). Vendors and dosing guides say the caps slow breakdown, so it hits harder and lasts longer than Semax, often quoting 2 to 3 times the potency. Nobody has measured that, and no published study has dosed a person or an animal with it. People take it for focus and drive by nasal spray or under the skin.

NAD+ is the coenzyme every cell burns to make energy and run repair enzymes. It is not a peptide, but it is sold like one: powder in a vial, mixed and injected. Home users inject 25 to 100 mg under the skin a few times a week; clinics drip 250 to 1,000 mg by IV. Swallowed NAD+ barely absorbs. No controlled human trial has set a subQ dose, and the IV data is small and rough on tolerability.

Oxytocin is the nine-amino-acid hormone your brain releases during birth, breastfeeding, touch and orgasm. As Pitocin it is an FDA-approved hospital drug for labor and bleeding after birth. Everything else people use it for, social ease, bonding and better sex, runs on compounded nasal sprays or research vials. Most nasal studies use 24 IU; the big trials for autism, obesity and female sexual function came out no better than placebo, while side effects at those doses were hard to tell from placebo too.

A small CNTF-derived peptide (Ac-DGGL(A)G-NH2, about 578 Da) made in Khalid Iqbal's lab, with an adamantylated glycine so it crosses into the brain and resists enzymes. In mice and rats it raised BDNF and new neurons and protected memory in Alzheimer's, aging and brain-injury models. No person has taken it in a trial. Users run 100 mcg to a few mg a day by nose or under the skin, numbers that come from vendors and forums.

A seven amino acid piece of spadin (residues 22 to 28 of the sortilin propeptide) that blocks the TREK-1 potassium channel. In mice it lifted depression-like behavior and grew new hippocampal cells within 4 days. It has never been dosed in a human study, so every human dose online is community convention.

PEG-MGF is mechano growth factor, the tail end of an IGF-1 variant that muscle makes after heavy loading or injury, with a polyethylene glycol (PEG) chain bolted on so it lasts longer. Plain MGF breaks down in minutes. Nobody has published what the PEG version's half-life actually is, and no human has ever been studied on it. Forum protocols run 200 to 400 mcg two or three times a week after training.

A three amino acid Khavinson bioregulator (Glu-Asp-Arg) pitched for brain aging, memory and stress. Russia sells it as a dietary supplement; elsewhere it comes as research vials. The only human dose we found in PubMed is 100 mcg by mouth twice a day, yet injection guides run anywhere from 100 mcg to 10 mg a day. The evidence is mostly cells and rats.

PT-141, or bremelanotide, is a 7-amino-acid peptide that turns up sexual desire through melanocortin receptors in the brain. It is FDA approved as Vyleesi, a 1.75 mg shot women take at least 45 minutes before sex, no more than once a day and 8 times a month. Men use it off label at 1 to 3 mg, often with Cialis. The trade-off is nausea: 40% got it in the phase 3 trials. Frequent dosing also darkens skin.

Retatrutide is a once-weekly injected peptide from Lilly that hits three receptors at once: GLP-1, GIP and glucagon. That makes it the first triple agonist in late trials. Phase 3 results put average weight loss in the high 20s percent at the top dose. It is not approved yet, so everything outside a trial is grey market.

A seven amino acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built on tuftsin, a small immune peptide, with the same Pro-Gly-Pro tail as Semax. Russia sells it over the counter as 0.15% nasal drops for anxiety. People use it for anxiety, social nerves, a racing mind at night, and to take the edge off Semax. Human data are a few small Russian trials. Not approved in the US.

Selank and Semax premixed in one vial, usually 5 mg of each in a 10 mg vial or 10 mg of each in 20 mg. Semax is run for focus and drive, Selank to take the edge off it. Guides dose 200 to 500 mcg of blend once or twice a day. The fixed ratio is the catch: you cannot move one without the other. No trial has tested the pair.

Semaglutide is a once-weekly GLP-1 receptor agonist from Novo Nordisk, a modified gut hormone built to last about a week in the blood. It is FDA approved as Ozempic, Rybelsus and Ozempic tablets for type 2 diabetes and as Wegovy for weight, heart risk and MASH, in weekly shots, daily tablets and a 7.2 mg high dose. Many people instead use compounded pharmacy vials or research-labeled powder, which have no trial data of their own. In STEP 1, 2.4 mg weekly averaged about 15% weight loss, and about two-thirds of it came back within a year of stopping.

A seven amino acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) made from a short piece of ACTH, with a Pro-Gly-Pro tail added for stability. Its label says it has none of ACTH's hormone activity. Russia registers it as 0.1% and 1% nasal drops for stroke recovery and brain function. People run it for focus and drive, by nose or injection. Human data are small Russian studies, mostly in stroke. Not approved in the US.

Sermorelin is the first 29 amino acids of your body's own GHRH, the shortest piece that still works. It tells the pituitary to release growth hormone in its normal pulses. It was once an FDA-approved drug (Geref) for children with GH deficiency, then pulled from the market for commercial reasons, not safety. Today it is a clinic and self-use staple at 200 to 300 mcg before bed.

SLU-PP-332 is not a peptide. It is a small synthetic molecule (290 g/mol) that switches on the estrogen-related receptors ERRα, β and γ, the genes muscle turns on during endurance training, which is why it gets called an exercise mimetic. In mice it made animals run about 70% longer and cut weight about 12% in obese mice. No human has taken it in a trial, and its own developers say it is not orally bioavailable, though most of it is sold as tablets.

An eight amino acid cosmetic peptide, also called acetyl octapeptide-3, sold for expression lines. It is a longer cousin of Argireline. Every human study tested it inside a product with other actives (microneedle patches, a serum), and no study has tested it injected. Most people use it as a serum; a few guides print injection doses anyway.

Recombinant human growth hormone: the full 191-amino-acid hormone, FDA approved since 1987 for children's growth disorders, adult GH deficiency and HIV wasting. Most people searching HGH want it for anti-aging, fat loss or bodybuilding, which is off-label, and US law makes distributing it for those uses a crime. Label doses are in mg; street vials are in IU, at 3 IU per mg.

A tiny four amino acid peptide that sticks to cardiolipin inside mitochondria. As elamipretide (Forzinity) it is the only longevity peptide here with an FDA approval, for Barth syndrome only. Trials use 40 mg a day; most users run 0.5 to 10 mg for energy, endurance and longevity. Fatigue is the most-posted complaint. Research vials are not the approved drug.

Survodutide is a once-weekly injected peptide from Boehringer Ingelheim, licensed from Zealand Pharma, that switches on two receptors: GLP-1 and glucagon. In the phase 3 SYNCHRONIZE-1 trial it cut body weight 12.2 to 13.0% at 76 weeks on the main analysis, and up to 16.6% for people who stayed on it. It also strips liver fat and is in phase 3 for MASH. It is approved nowhere, so every vial sold outside a trial is grey market.

In the analytical and anti-doping literature, TB-500 is Ac-LKKTETQ: a 7 amino acid fragment (residues 17 to 23, about 889 Da) of the 43 amino acid protein thymosin beta-4. What ships in a vial labelled TB-500 varies. People run it for soft-tissue recovery, usually with BPC-157, on a loading then maintenance schedule. Every human trial used the full protein, not the fragment.

Tesamorelin is the only GHRH analog with current FDA approval. It makes your pituitary release more of your own growth hormone, which raises IGF-1. In Phase 3 trials it cut visceral belly fat by about 15% in adults with HIV-related fat gain. That approval and that data are why it stands apart from every other GH peptide. Off label, people run it for belly fat and recomposition.

A Russian immune drug made from calf thymus: a mix of small peptides, not one molecule. Registered in Russia for immune deficiency at 5 to 20 mg into muscle daily for 3 to 10 days. Its fame comes from Khavinson's longevity cohort, which reported half the mortality with thymalin and lower still when combined with epithalamin, the extract behind epitalon. That data comes from one research group and has not been replicated in the West.

A 28 amino acid thymus peptide that nudges T-cell immunity. Unlike most research peptides it has a label dose: as Zadaxin, approved outside the US for hepatitis B and C at 1.6 mg twice a week. Big trials are mixed: a 1,106-patient sepsis trial was null and the Cochrane hepatitis B review rates the evidence very low certainty. Not FDA approved; an FDA advisory committee voted 17 to 4 against compounding it.

Thymosin beta-4 is the full 43 amino acid protein (about 4,963 Da) that cells use to hold actin in reserve for movement and repair. It has real human trials: IV safety studies, wound gels and eye drops. TB-500 is a 7 amino acid piece of it, and sellers use the names interchangeably. No trial has tested it as a subQ injection.

Tirzepatide is a once-weekly injectable peptide from Lilly that hits two gut-hormone receptors, GIP and GLP-1. It is FDA approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and sleep apnea with obesity. In SURMOUNT-1, people on 15 mg lost about 21% of body weight. Outside the label, people run compounded or research vials, slow titrations, microdoses and split doses. Those off-label patterns have no trials behind them. Online sellers often call it "GLP-2", which is a nickname for second generation, not a different drug.

A 28-amino-acid neuropeptide the body makes in the gut, brain, lungs and immune system. It relaxes blood vessels and airways and calms inflammation. Most people who use it do so as a compounded nasal spray, the final step of the Shoemaker protocol for mold illness (CIRS). Its human evidence is real but patchy: an approved ED injection in Europe, small inhaled studies, and a large COVID trial that failed.